← Leaderboards
Myles C Cabot
John Wayne Cancer Institute
$5,230,450
Attributed
$6,212,322
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2007–23$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,121,038 · 7
By mechanism
P01$6,940,057 · 3
R01$2,358,308 · 2
R21$822,673 · 2
Top collaborators
- Mark Kester5 shared
- Thomas P Loughran2 shared
Others in their field
Top investigators on “Ceramides”
- Yusuf Awni Hannun · Medical University Of South Carolina$31,236,776
- Besim Ogretmen · Medical University Of South Carolina$16,800,540
- Scott A Summers · Colorado State University-Fort Collins$15,094,141
- Pin-Lan Li · Medical College Of Wisconsin$14,567,134
- Richard N Kolesnick · Sloan-Kettering Inst Can Research$13,993,408
- Susan J Sumner · Research Triangle Institute$13,509,958
Research focus
CeramidesApoptosisDrug ResistanceMalignant NeoplasmsMetabolismCancer CellLipidsCellsResponseMulti-Drug ResistanceGlycosylationGenerationsChemotherapyCell LinePlayP-GlycoproteinGlucosylceramidesInhibitor/AntagonistInnovationIn VivoCytotoxicityP-GlycoproteinsPharmaceutical PreparationsEffective Therapy
Grant awards (23)
Targeted Sphingolipid Metabolism for Treatment of AML$1,954,358
P01 · FY2023 · CA
Targeting Ceramide Glycosylation in AML$258,560
P01 · FY2023 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$1,954,358
P01 · FY2022 · CA
Targeting Ceramide Glycosylation in AML$258,560
P01 · FY2022 · CA · contact PI
Targeting Ceramide Glycosylation in AML$263,836
P01 · FY2021 · CA · contact PI
Targeting Ceramide Glycosylation in AML$286,641
P01 · FY2020 · CA · contact PI
Targeting Ceramide Glycosylation in AML$387,720
P01 · FY2017 · CA · contact PI
Targeting Ceramide Glycosylation in AML$387,720
P01 · FY2016 · CA · contact PI
Targeting Ceramide Glycosylation in AML$394,165
P01 · FY2015 · CA · contact PI
Targeting Ceramide Glycosylation in AML$391,023
P01 · FY2014 · CA · contact PI
Targeting Ceramide Glycosylation in AML$403,116
P01 · FY2013 · CA · contact PI
Assessing pancreatic cancer susceptibility to ceramide-mediated cell death.$198,950
R21 · FY2011 · CA · contact PI
Ceramide, Membrane Glycolipids and Glycoprotein Expression$519,933
R01 · FY2010 · GM · contact PI
Assessing pancreatic cancer susceptibility to ceramide-mediated cell death.$246,123
R21 · FY2010 · CA · contact PI
Ceramide, Membrane Glycolipids and Glycoprotein Expression$436,967
R01 · FY2009 · GM · contact PI
Ceramide, Membrane Glycolipids and Glycoprotein Expression$86,593
R01 · FY2009 · GM · contact PI
Ceramide, Membrane Glycolipids and Glycoprotein Expression$445,797
R01 · FY2008 · GM · contact PI
Ceramide, Membrane Glycolipids and Glycoprotein Expression$43,200
R01 · FY2008 · GM · contact PI
Ceramide, Membrane Glycolipids and Glycoprotein Expression$381,124
R01 · FY2007 · GM · contact PI
TARGETING CERAMIDE METABOLISM FOR CANCER TREATMENT$188,800
R21 · FY2003 · CA
TARGETING CERAMIDE METABOLISM FOR CANCER TREATMENT$188,800
R21 · FY2002 · CA
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS$225,901
R01 · FY2001 · CA
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS$218,793
R01 · FY2000 · CA